

V čase diagnózy endoskopista aktivně zjišťuje anamnézu od pacienta i z informačního systému, zda byla u pacienta provedena gastroscopie v posledních 3 letech a s jakým výsledkem. Pokud předchozí gastroscopie nádor nezjistila, jedná se o PEUGIC.

- Součástí sledování PEUGIC na každém pracovišti by měla být i analýza jednotlivých příčin vedoucích k PEUGIC. Jako návod

k této analýze může sloužit systém analýzy příčin, který vytvořil Kamran a kolektiv (Schéma 1).

- Klíčem ke zvýšení kvality horní endoskopie v našich zemích jsou Standardy kvality České gastroenterologické společnosti pro gastroscopii, jejichž stanoviska by měla být známa všem endoskopistům a měla by být dodržována na všech endoskopických jednotkách v České republice.

LITERATURA

- Alexandre L, Tsilegeridis-Legeris T, Lam S. Clinical and Endoscopic Characteristics Associated With Post-Endoscopy Upper Gastrointestinal Cancers: A Systematic Review and Meta-analysis. *Gastroenterology*. 2022;162(4):1123-1135. Available from DOI: <https://doi.org/10.1053/j.gastro.2021.12.270>.
- Chen D, Fu M, Chi L. Prognostic and predictive value of a pathomics signature in gastric cancer. *Nat Commun*. 2022;13(1):6903. Available from DOI: <https://doi.org/10.1038/s41467-022-34703-w>.
- Liu ChQ, Ma YL, Qin Q. Epidemiology of esophageal cancer in 2020 and projections to 2030 and 2040. *Thorac Cancer*. 2023;14(1):3-11. Available from DOI: <https://doi.org/10.1111%2F1759-7714.14745>.
- Novotvary 2018 ČR. Data z 2018. Ústav zdravotnických informací a statistiky ČR. [cit.2021-04-25]. Available from [www: https://www.uzis.cz/res/008352/novotvary2018.pdf](http://www.uzis.cz/res/008352/novotvary2018.pdf).
- Martinek J, Trunecka P, et al. Gastroenterologie a hepatologie v algoritmech. Maxdorf: Praha 2021: 143-154. ISBN 978-80-7345-684-9.
- Holmberg D, Santoni G, Euler-Chelpin MC, et al. Incidence and Mortality in Upper Gastrointestinal Cancer After Negative Endoscopy for Gastroesophageal Reflux Disease. *Gastroenterology* 2022;162(2):431-438. Available from DOI: <https://doi.org/10.1053/j.gastro.2021.10.003>.
- Goetz N, Lamba M, Ryan K, et al. Post-Endoscopy Upper Gastrointestinal Cancer Rate in a Tertiary Referral Centre: An Australian Data Linkage Analysis. *J Gastrointest Cancer* 2022; online ahead of print. Available from <https://doi.org/10.1007/s12029-022-00874-4>.
- Menon S, Trudgill N. How commonly is upper gastrointestinal cancer missed at endoscopy? A meta-analysis. *Endosc Int Open* 2014; 2(2): e46-e50. Available from DOI: <https://doi.org/10.1055/s-0034-1365524>.
- Chadwick G, Groene O, Hoare J, et al. A population-based, retrospective, cohort study of esophageal cancer missed at endoscopy. *Endoscopy*. 2014;46 (7):553-560. Available from DOI: <https://doi.org/10.1055/s-0034-1365646>.
- Chadwick G, Groene O, Riley S, et al. Gastric cancers missed during endoscopy in England. *Clin Gastroenterol Hepatol*. 2015;13(7):1264-1270. Available from DOI: <https://doi.org/10.1016/j.cgh.2015.01.025>.
- Pimenta-Melo AR, Monteiro-Soares M, Libânio D, et al. Missing rate for gastric cancer during upper gastrointestinal endoscopy: a systematic review and meta-analysis. *Eur J Gastroenterol Hepatol*. 2016;28(9):1041-1049. Available from DOI: <https://doi.org/10.1097/meg.0000000000000657>.
- Cheung D, Menon S, Hoare J, et al. Factors associated with upper gastrointestinal cancer occurrence after endoscopy that did not diagnose cancer. *Dig Dis Sci*. 2016;61(9):2674-2684. Available from DOI: <https://doi.org/10.1007/s10620-016-4176-4>.
- Kamran U, King D, Abbasi A, et al. A root cause analysis system to establish the most plausible explanation for post-endoscopy upper gastrointestinal cancer. *Endoscopy*. 2023; 55(2):109-118. Available from DOI: <https://doi.org/10.1055/a-1917-0192>.
- Januszewicz W, Witczak K, Wieszczy P, et al. Prevalence and risk factors of upper gastrointestinal cancers missed during endoscopy: a nationwide registry-based study. *Endoscopy*. 2022;54(7):653-660. Available from DOI: <https://doi.org/10.1055/a-1675-4136>.
- Beg S, Ragunat K, Wyman A, Banks M, Trudgill N, Pritchard D, et al. Quality standards in upper gastrointestinal endoscopy: a position statement of the British Society of Gastroenterology (BSG) and Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland (AUGIS). *Gut*. 2017;66(11):1886-1899. Available from DOI: <https://doi.org/10.1136/gutjnl-2017-314109>.
- Bisschops R, Areia M, Coron E, Dobru D, Kaskas B, Kuvaev R, et al. Performance measures for upper gastrointestinal endoscopy: a European Society of Gastrointestinal Endoscopy (ESGE) Quality Improvement Initiative. *Endoscopy*. 2016;48(9):843-864. Available from DOI: <http://dx.doi.org/10.1055/s-0042-113128>.
- Januszewicz W, Kaminski MF. Quality indicators in diagnostic upper gastrointestinal endoscopy. *Therapeutic Advances in Gastroenterology*. 2020;13:1-19. Available from DOI: <https://doi.org/10.1177%2F1756284820916693>.
- Cyrany J, Baliar K, Falt P, et al. Gastroscopie – standardy kvality České gastroenterologické společnosti ČLS JEP. *Gastroent Hepatol*. 2022;76(3):194-211. Dostupné z DOI: <https://doi.org/10.48095/ccgh2022194>.
- Fujita S. Biology of early gastric carcinoma. *Pathol Res Pract*. 1978;163 (4):297-309. Available from DOI: [https://doi.org/10.1016/s0344-0338\(78\)80028-4](https://doi.org/10.1016/s0344-0338(78)80028-4).
- Yalamarthi S, Witherspoon P, McCole D, et al. Missed diagnoses in patients with upper gastrointestinal cancers. *Endoscopy*. 2004;36(10):874-879. Available from DOI: <https://doi.org/10.1055/s-2004-825853>.
- Stepan M, Falt P, Pipek B, et al. Administration of mucolytic solution before upper endoscopy – double-blind, monocentric, randomized study. *Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic*. 2023;167(1):69-73. Available from DOI: <https://doi.org/10.5507/bp.2021.038>.
- Elvas L, Areia M, Brito D, Alves S, Saraiva S, Cadime AT. Premedication with simethicone and N-acetylcysteine in improving visibility during upper endoscopy: a double-blind randomized trial. *Endoscopy*. 2017;49(2):139-145. Available from DOI: <http://dx.doi.org/10.1055/s-0042-119034>.
- Stepan M, Fojtik P, Falt P, et al. Administration of maximum dose of mucolytic solution before upper endoscopy—a double-blind, randomized trial. *Eur J Gastroenterol Hepatol*. 2023;35(6):635-640. Available from DOI: <https://doi.org/10.1097/meg.0000000000002559>.
- Manfredi G, Berte R, Liritano E, et al. Premedication with simethicone and N-acetylcysteine for improving mucosal visibility during upper gastrointestinal endoscopy in a Western population. *Endosc Int Open*. 2021; 09(02): E190-E194. Available from DOI: <https://doi.org/10.1055/a-1315-0114>.
- Wang YR, Loftus EV, Judge TA, et al. Rate and predictors of interval esophageal and gastric cancers after esophagogastroduodenoscopy in the United States. *Digestion*. 2016; 94(3):176-180. Available from DOI: <https://doi.org/10.1159/000452794>.
- Hernanz N, Rodriguez de Santiago E, Marcos Prieto HM et al. Characteristics and consequences of a missed gastric cancer: a multicentric cohort study. *Dig Liver Dis*. 2019; 51(6): 894-900. Dostupné z DOI: <https://doi.org/10.1016/j.dld.2019.02.006>.
- Rodriguez de Santiago E, Hernanz N, Marcos-Prieto HM, et al. Rate of missed oesophageal cancer at routine endoscopy and survival outcomes: A multicentric cohort study. *United European Gastroenterol J*. 2019;7(2):189-198. Available from DOI: <https://doi.org/10.1177/2050640618811477>.
- Rutter MD, Beintaris I, Valori R, et al. World Endoscopy Organization consensus statements on post-colonoscopy and post-imaging colorectal cancer. *Gastroenterology* 2018;155(3):909-925. Available from DOI: <https://doi.org/10.1053/j.gastro.2018.05.038>.
- Jin S, Jeon SW, Kwon Y, et al. Optimal endoscopic screening interval for early detection of gastric cancer: a single-center study. *J Korean Med Sci*. 2018;33(23):e166. Available from DOI: <https://doi.org/10.3346%2Fjkms.2018.33.e166>.
- Cho YS, Chung IK, Kim JH, et al. Risk factors of developing interval early gastric cancer after negative endoscopy. *Dig Dis Sci*. 2015;60(4):936-43. Available from DOI: <https://doi.org/10.1007/s10620-014-3384-z>.
- Beck M, Bringeland EA, Qvigstad G, et al. Gastric Cancers Missed at Upper Endoscopy in Central Norway 2007 to 2016—A Population-Based Study. *Cancers*. 2021;13(22): 5628. Available from DOI: <https://doi.org/10.3390/cancers13225628>.
- PGD Guillena, VJM Alvarado, MJ Ramiro, et al. Gastric cancer missed at esophagogastroduodenoscopy in a well-defined Spanish population. *Dig Liver Dis*. 2019;51(8):1123-1129. Available from DOI: <https://doi.org/10.1016/j.dld.2019.03.005>.
- Gavric A, Hanzel J, Zagar T, et al. Survival outcomes and rate of missed upper gastrointestinal cancers at routine endoscopy: a single center retrospective cohort study. *Eur J Gastroenterol Hepatol*. 2020;32(10):1312-1321. Available from DOI: <https://doi.org/10.1097/MEG.0000000000001863>.
- Januszewicz W, Wieszczy P, Bialek A, et al. Endoscopist biopsy rate as a quality indicator for outpatient gastroscopy: a multicenter cohort study with validation. *Gastrointest Endosc*. 2019;89(6):1141-1149. Available from DOI: <https://doi.org/10.1016/j.gie.2019.01.008>.
- Tai FW, Wray N, Sidhu R, et al. Factors associated with oesophagogastric cancers missed by gastroscopy: a case-control study. *Frontline Gastroenterol*. 2019;11:194-201. Available from DOI: <http://dx.doi.org/10.1136/flgastro-2019-101217>.
- van Putten M, Johnston BT, Murray LJ, et al. Missed oesophageal adenocarcinoma and high-grade dysplasia in Barrett's oesophagus patients: a large population-based study. *United European Gastroenterol J*. 2018;6 (4):519-528. Available from DOI: <https://doi.org/10.1177/2050640617737466>.